Source comparison
Best MK-677 Dosage for Oral GH Secretagogue: Research vs Clinical Comparison
5–10mg 40–55% 25–40% Low (<15% report appetite/water retention) Long-term bone studies, cognitive protocols Subtherapeutic for lean mass studies but viable for extended protocols where tolerability matters more than peak GH output 10–15mg 55–75% 40–60% Moderat
This comparison does not assign a generated winner or score.
- 5–10mg
- 40–55%
- 25–40%
- Low (<15% report appetite/water retention)
- Long-term bone studies, cognitive protocols
- Subtherapeutic for lean mass studies but viable for extended protocols where tolerability matters more than peak GH output
- 10–15mg
- 55–75%
- 40–60%
- Moderate (20–30% appetite, minimal insulin effect)
- Standard research starting dose, elderly populations
- Optimal starting point for most applications. Allows assessment of individual response before escalation
- 20–25mg
- 85–100%
- 70–90%
- Moderate-High (30–40% appetite, mild glucose elevation)
- Lean mass protocols, muscle protein synthesis studies
- Sweet spot for anabolic research. Receptor saturation achieved without excessive side effect burden
- 30–40mg
- 75–90%
- 80–100%
- High (50–65% appetite, measurable insulin resistance)
- Rarely justified in research settings
- Diminishing returns become evident. GH output often lower than 25mg due to negative feedback
- 50mg+
- 65–85%
- 90–110%
- Very High (>70% appetite, glucose dysregulation common)
- Not recommended in peer-reviewed protocols
- Side effects exceed benefits. Used only in legacy studies before dose-response curves were characterized